Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Roseville › NPI 1356390264
Hospital

Sutter Valley Hospitals

Sutter Valley Hospitals was paid $81.16M by Medicaid between Jan 2018 and Dec 2024, across 238 billing codes. Its largest line is 0450, Emergency room services — 16% of everything it billed.

33Billing provider infoSUTTER VALLEY HOSPITALS
ROSEVILLE, CA 95661
33aNPI1356390264assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$81.16M
24GClaims1,053,281
24DCodes billed238
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#32 of 410
Median peer was paid$6.90M
This provider vs. median12×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$1.0M$2.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2018131,284$8.30M
2019119,432$7.52M
202098,313$6.67M
2021143,967$12.71M
2022168,799$13.89M
2023209,480$18.20M
2024incomplete182,006$13.87M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
0450 Emergency room services 16% 78,944 70,685 $13.34M
99199 Unlisted special service, procedure or report 13% 51,361 43,398 $10.67M
74177 Computed tomography, abdomen and pelvis; with contrast material 6.6% 8,530 8,201 $5.34M
70450 Computed tomography, head or brain; without contrast material 5.2% 9,727 9,330 $4.26M
72125 Computed tomography, cervical spine; without contrast material 3.9% 4,135 3,996 $3.20M
99281 Emergency department visit for the evaluation and management, self-limited or minor 2.8% 14,157 12,707 $2.26M
71260 Computed tomography, thorax, diagnostic; with contrast material 2.2% 1,750 1,691 $1.77M
80053 Comprehensive metabolic panel 2.1% 62,661 56,200 $1.69M
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 2.0% 6,786 6,637 $1.59M
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.9% 16,161 14,929 $1.55M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.6% 10,863 9,991 $1.32M
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report 1.5% 26,422 24,527 $1.25M
226 more codes
74176 Computed tomography, abdomen and pelvis; without contrast material 1.5% 4,924 $1.20M
96375 Therapeutic injection; each additional sequential IV push 1.4% 15,261 $1.14M
0250 1.3% 18,116 $1.05M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.3% 73,211 $1.03M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 1.2% 12,612 $981K
82077 1.2% 8,060 $948K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 1.1% 3,738 $872K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour 1.1% 7,314 $872K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 17,761 $800K
96361 Intravenous infusion, hydration; each additional hour <1% 10,208 $750K
J3490 Unclassified drugs <1% 46,458 $700K
71045 Radiologic examination, chest; single view <1% 16,504 $691K
72131 <1% 1,457 $658K
0762 <1% 1,536 $635K
71046 Radiologic examination, chest; 2 views <1% 14,472 $620K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 1,150 $583K
71275 Computed tomographic angiography, chest, with contrast material <1% 1,638 $578K
96376 <1% 1,635 $533K
80143 <1% 4,778 $485K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 11,734 $473K
80179 <1% 4,660 $462K
70486 <1% 729 $461K
84484 <1% 23,883 $450K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 4,145 $444K
0160 <1% 567 $428K
99285 Emergency room visit (most serious) <1% 1,650 $426K
93971 <1% 2,200 $417K
99283 Emergency room visit (moderate) <1% 4,302 $411K
T1999 Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" <1% 16,198 $406K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 3,790 $402K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 3,375 $401K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 3,114 $383K
99284 Emergency room visit (serious) <1% 2,514 $367K
0270 <1% 12,265 $353K
83690 <1% 23,171 $338K
Z7502 <1% 9,027 $329K
70551 Magnetic resonance imaging, brain; without contrast material <1% 444 $315K
76830 Ultrasound, transvaginal <1% 2,625 $314K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 467 $307K
70498 <1% 640 $301K
70496 <1% 596 $256K
99202 Office or other outpatient visit for the evaluation and management of a new patient, straightforward <1% 1,420 $250K
80048 Basic metabolic panel (calcium, ionized) <1% 7,105 $249K
83880 <1% 5,511 $242K
J7030 Infusion, normal saline solution , 1000 cc <1% 17,652 $236K
87040 <1% 9,186 $225K
76801 <1% 2,118 $225K
87086 Culture, bacterial; quantitative colony count, urine <1% 16,759 $220K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 3,416 $188K
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 5,248 $185K
81001 <1% 27,707 $182K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 3,092 $180K
99499 <1% 2,850 $177K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 357 $171K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 2,328 $171K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 2,317 $168K
82803 <1% 5,110 $168K
72128 <1% 331 $160K
73630 <1% 2,975 $156K
73610 <1% 2,633 $154K
73030 <1% 2,184 $153K
71250 <1% 344 $151K
83605 <1% 7,858 $145K
0510 <1% 2,212 $142K
73130 <1% 1,967 $139K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 1,325 $137K
84443 Thyroid stimulating hormone (TSH) <1% 4,726 $137K
83735 <1% 10,795 $131K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 950 $130K
A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose <1% 396 $116K
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 1,631 $111K
81025 <1% 9,211 $108K
86850 <1% 2,425 $108K
85730 <1% 5,570 $107K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 10,959 $107K
0360 <1% 489 $103K
73110 <1% 1,499 $103K
93970 <1% 348 $102K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,072 $100K
73562 <1% 1,836 $99K
70491 <1% 216 $99K
85610 <1% 9,968 $98K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 9,015 $94K
85379 <1% 4,521 $85K
87486 <1% 1,075 $83K
87581 <1% 1,074 $83K
84702 <1% 5,877 $82K
90715 <1% 967 $79K
86901 <1% 4,445 $79K
J7120 Ringers lactate infusion, up to 1000 cc <1% 6,580 $78K
86900 <1% 4,586 $77K
J1170 Injection, hydromorphone, up to 4 mg <1% 4,655 $73K
J2785 Injection, regadenoson, 0.1 mg <1% 183 $70K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 6,205 $69K
41899 Unlisted procedure, dentoalveolar structures <1% 734 $68K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 215 $66K
81003 <1% 14,345 $64K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 4,453 $63K
93017 <1% 483 $56K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,468 $55K
J2270 Injection, morphine sulfate, up to 10 mg <1% 3,917 $54K
76770 <1% 333 $53K
73080 <1% 717 $51K
73502 <1% 583 $49K
73560 <1% 787 $49K
76497 <1% 18 $48K
76815 Ultrasound, pregnant uterus, real time with image documentation, limited <1% 698 $46K
Z9725 <1% 1,454 $45K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 4,723 $45K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 316 $44K
84703 <1% 8,889 $44K
73590 <1% 615 $42K
97750 <1% 366 $42K
72100 <1% 773 $40K
87077 <1% 3,954 $37K
96413 Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance <1% 292 $36K
87186 <1% 3,712 $35K
76870 <1% 335 $34K
82550 <1% 2,881 $33K
J2060 Injection, lorazepam, 2 mg <1% 2,860 $32K
82552 <1% 1,300 $31K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 2,828 $31K
80076 <1% 939 $30K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 3,014 $30K
87634 <1% 300 $30K
84145 <1% 851 $28K
J3475 Injection, magnesium sulfate, per 500 mg <1% 2,212 $28K
73090 <1% 363 $26K
74018 <1% 686 $25K
84132 <1% 880 $24K
82330 <1% 945 $23K
86140 <1% 2,417 $23K
87081 <1% 1,541 $21K
72141 <1% 25 $21K
G0378 Hospital observation service, per hour <1% 425 $20K
82947 <1% 2,489 $19K
96367 <1% 292 $19K
36415 Collection of venous blood by venipuncture <1% 16,822 $18K
94644 <1% 497 $17K
0760 <1% 258 $16K
87400 <1% 1,570 $15K
59025 Fetal non-stress test <1% 793 $15K
J0780 Injection, prochlorperazine, up to 10 mg <1% 683 $15K
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 612 $15K
0710 <1% 291 $14K
99201 <1% 131 $13K
J1815 Injection, insulin, per 5 units <1% 796 $13K
82150 <1% 175 $12K
87430 <1% 693 $12K
S0028 Injection, famotidine, 20 mg <1% 534 $12K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 328 $11K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 709 $10K
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 761 $9K
72148 Magnetic resonance imaging, lumbar spine; without contrast material <1% 13 $9K
J0137 Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg <1% 340 $9K
72170 <1% 29 $9K
73700 <1% 25 $8K
73140 <1% 238 $8K
85652 <1% 1,996 $8K
99282 Emergency department visit for the evaluation and management, low to moderate severity <1% 64 $8K
J3480 Injection, potassium chloride, per 2 meq <1% 130 $8K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 717 $7K
83036 Hemoglobin; glycosylated (A1C) <1% 390 $7K
71020 <1% 166 $7K
S0164 Injection, pantoprazole sodium, 40 mg <1% 328 $6K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 668 $6K
A9585 Injection, gadobutrol, 0.1 ml <1% 56 $6K
J2704 Injection, propofol, 10 mg <1% 482 $5K
73060 <1% 73 $5K
87210 <1% 535 $5K
84295 <1% 633 $4K
10060 <1% 57 $4K
93976 <1% 14 $4K
73552 <1% 40 $4K
87420 <1% 214 $3K
80061 Lipid panel <1% 269 $3K
Z7610 <1% 363 $3K
0324 <1% 15 $3K
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 1,753 $3K
J3360 Injection, diazepam, up to 5 mg <1% 121 $3K
84439 <1% 185 $3K
72040 <1% 56 $3K
87147 <1% 285 $3K
29125 <1% 120 $3K
J7050 Infusion, normal saline solution, 250 cc <1% 207 $3K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 327 $3K
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 745 $2K
87088 <1% 352 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 34 $2K
J8540 Dexamethasone, oral, 0.25 mg <1% 928 $2K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 88 $2K
86308 <1% 218 $2K
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 936 $2K
J0690 Injection, cefazolin sodium, 500 mg <1% 166 $2K
J2919 Injection, methylprednisolone sodium succinate, 5 mg <1% 72 $2K
85027 <1% 252 $1K
J1650 Injection, enoxaparin sodium, 10 mg <1% 96 $1K
84100 <1% 252 $1K
12011 <1% 13 $1K
J0665 Injection, bupivicaine, not otherwise specified, 0.5 mg <1% 344 $1K
88300 <1% 121 $1K
74022 <1% 13 $980.66
J7644 Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram <1% 239 $974.69
J1171 Injection, hydromorphone, 0.1 mg <1% 51 $840.93
12001 <1% 25 $833.05
82010 <1% 57 $790.67
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 28 $699.93
72070 <1% 13 $612.18
99070 <1% 19 $576.10
J1630 Injection, haloperidol, up to 5 mg <1% 42 $467.09
S0077 Injection, clindamycin phosphate, 300 mg <1% 14 $424.05
J2470 Injection, pantoprazole sodium, 40 mg <1% 74 $412.25
J2003 Injection, lidocaine hydrochloride, 1 mg <1% 45 $388.52
J3370 Injection, vancomycin hcl, 500 mg <1% 16 $373.08
87205 <1% 44 $346.98
81015 <1% 60 $334.67
29515 <1% 13 $319.08
87070 <1% 14 $246.24
84550 <1% 40 $227.73
82270 <1% 27 $175.68
G8978 Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals <1% 19 $170.38
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 60 $74.60
86592 <1% 13 $47.48
83550 <1% 12 $27.28
83540 <1% 12 $23.20
G8979 Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting 0% 19 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCONFORTI, JAMES (PRESIDENT/CEO)
Parent organizationSUTTER VALLEY HOSPITALS
Same official

Other billing entities under CONFORTI, JAMES

Full network →
ProviderLocationPaid
Sutter Valley HospitalsVallejo, CA$33.28M
Sutter Valley HospitalsDavis, CA$20.04M
Sutter Valley HospitalsAuburn, CA$15.54M
Sutter Valley HospitalsJackson, CA$11.20M
Sutter Valley HospitalsSacramento, CA$3.16M
Sutter Valley HospitalsAuburn, CA$165K
Sutter Valley HospitalsAuburn, CA$25K
Sutter Valley HospitalsSacramento, CA$71.31
Sutter Valley HospitalsRoseville, CA$0.00

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.